Therapeutic agent for irritable bowel syndrome
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 24, 2012
Grant Date -
Apr 9, 2009
app pub date -
Apr 19, 2006
filing date -
Apr 21, 2005
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
It was shown that bombesin 2 (BB2) receptor antagonists typified by RC-3095 are therapeutic agents for irritable bowel syndrome (IBS), and show excellent efficacy in treating both an abdominal symptom and bowel movement disorder. Thus, the present invention provides a therapeutic agent for irritable bowel syndrome (IBS) which comprises, as an active ingredient, a bombesin 2 (BB2) receptor antagonist as well as a method for treating IBS.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully